Irvine heart defibrillator maker Cardiac Science Inc. said Tuesday that Chinese regulators approved its latest Powerheart line of defibrillators.
The approval allows Cardiac to sell to China its automated external defibrillators, which deliver tiny life-saving shocks to people in cardiac arrest and are designed for use in public places.
Cardiac shares finished up 9.5% in trading Tuesday to $1.04. The company’s stock has traded as high as $3.42 within the past year, but has been trading below $1 for the better part of the past few months.
Cardiac, which is awaiting regulatory approval on its pending combination with Quinton Cardiology Corp. of Bothell, Wash., sells most of its products in the U.S., but international sales account for some 40% of its revenue.
More than 100 of its earlier-generation Powerheart bedside cardiac monitors are being used in Chinese hospitals, the company said.
